Safety and Efficacy Study of CTX112 for B-Cell Malignancies
This study is testing a treatment called CTX112 for people with B-cell malignancies (cancers of certain white blood cells) that have returned or not responded to previous treatments. CTX112 is an immunotherapy that uses your own modified immune cells to fight cancer. The study aims to see how safe CTX112 is and how well it works. To join, you must be at least 18 years old, have a B-cell malignancy that has relapsed or is refractory, and be in good general health. The study will measure side effects in the first 28 days and how many people respond to the treatment for up to 60 months. The current status of this study is unclear, and it plans to enroll 120 participants.
- Study design
- This is an open-label, multi-center study, meaning both you and your doctors will know you are receiving CTX112. It is a Phase 1/2 study, which typically looks at safety first, then effectiveness.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- You would be followed for up to 60 months (5 years) after receiving CTX112 to see how well the treatment works.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
At a glance
Conditions
Where it's being run
7 sites across 7 statesStudy leadership
- Melanie Allen, M.Sc. · STUDY_DIRECTOR · CRISPR Therapeutics
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Phase 1 (Dose Escalation): Incidence of adverse events, defined as dose-limiting toxicitiesFrom CTX112 infusion up to 28 days post-infusion
- Phase 2 (Cohort Expansion): Objective response rateFrom CTX112 infusion up to 60 months post-infusion